You are here

TOPIC 366: I-PARTS INTEGRATED PLATFORM FOR ANTI-CANCER RADIATION THERAPEUTICS SCREENING

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 75N91019C00043
Agency Tracking Number: N44CA190043
Amount: $1,964,216.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: N/A
Timeline
Solicitation Year: 2018
Award Year: 2019
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
22 MONTOYA CIR
BRANFORD, CT 06405-2546
United States
DUNS: 079364420
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Rao Papineni
 (832) 687-4334
 docpapineni@gmail.com
Business Contact
 Rao Papineni
Phone: (832) 687-4334
Email: docpapineni@gmail.com
Research Institution
N/A
Abstract

Tumor Irradiation during cancer treatment induces clonogenic death that can be best assessed by colony forming assaysThese colony forming assays are laborious and never utilized in high throughput screeningHTSformatsWe propose to develop anintegrated platform for HTS clonogenic survival assayfor cancer drug screening as well as radiation effect modulation screeningNamedI PARTSIntegrated platform for anti cancer radiation therapeutics screening combines the recent technological advances in cell culture automationmicrofluidicsand high speed image analysis along with NIST traceable dosimetry based HTS X ray irradiationThe I PARTS adopts modular multimodal microscopy to capture the real time colony growth with phase contrastluminescencefluorescence or physical features through tomographyCommerciallythe product has the scope and feasibility to analyze various cancer drugs with variable X ray dosesand simultaneously in different cell linesFutherthis novel single cell array clonogenic platforms will allow improved plating efficiency in clonogenic assay systemsExperimental validation and commercialization will be pursued during this proposalI PARTSan integrated instrument is designed and developed to discover new cancer drugs required for combined cancer therapyThis instrument and the technology is miniaturized such that cancer drugs and radiation treatment can be tailored for individual patientsthe ongoing goal of personalized medicine

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government